Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | TLR4 | O00206 | 8/20 | 0.41 |
| ▸ | TLR2 | O60603 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674527 | 0.85 | NPC1 (0.41) | TLR4TLR2NPC1HSP90AA1SRC | |
| SCHEMBL677841 | 0.85 | NPC1 (0.41) | TLR4TLR2NPC1HSP90AA1SRC | |
| SCHEMBL678635 | 0.83 | PTGDR2 (0.46) | PTGDR2SRCMETALDH1A1CYP2C19 | |
| SCHEMBL675512 | 0.76 | PTGDR2 (0.48) | PTGDR2SRCMETALDH1A1CYP2C19 | |
| SCHEMBL679106 | 0.73 | SRC (0.48) | PTGDR2SRCMETALDH1A1CYP2C19 | |
| SCHEMBL3671974 | 0.72 | IP6K1 (0.41) | PTGDR2SRCALDH1A1KMT2ACYP2C19 | |
| SCHEMBL678637 | 0.72 | PTGDR2 (0.47) | PTGDR2SRCCYP2C19 | |
| SCHEMBL675484 | 0.71 | SRC (0.40) | SRCALDH1A1 | |
| SCHEMBL675465 | 0.71 | IP6K1 (0.38) | PTGDR2SRCALDH1A1CYP2C19 | |
| SCHEMBL679195 | 0.71 | SRC (0.40) | SRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | PTGDR2 3291/4885TLR4 2984/4885TLR2 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.